Technoscience Continues Its Growth in the Biotech Sector, strengthening international scientific dialogue with Gregg L. Semenza, 2019 Nobel Laureate in Physiology or Medicine, through the scientific liaison and networking activities of the Prof. Matteo Antonio Russo.
The collaboration is part of the strategy of the Technoscience Science Park, aimed at consolidating an ecosystem capable of connecting biomedical research, academic expertise, industrial innovation and technology transfer. Biotechnology is now one of the most important fields for the development of innovative medicine, applied research and new solutions for health, prevention and quality of life.
The Scientific Value of the Dialogue with Gregg L. Semenza
The dialogue with Gregg L. Semenza is particularly significant given the Nobel Laureate's scientific profile, internationally recognised for his studies on the mechanisms by which cells sense and respond to oxygen availability.
This is a field of research that has profoundly influenced our understanding of biological processes related to hypoxia, cellular regulation and the future prospects of molecular medicine. In this direction, scientific dialogue with Semenza helps strengthen Technoscience's positioning in biotech, a sector that is increasingly central to the connection between frontier science, clinical applications and technological development.
A Scientific Network for Biomedical Research and Innovative Medicine
For Technoscience, this pathway is not an isolated initiative, but a step within a broader strategy: building a biotech network capable of connecting science, business and industrial development.
In recent months, the Science Park has intensified its dialogue with high-profile figures in national and international research, strengthening a scientific scope that includes molecular cardiology, regenerative medicine, cell biology, pharmacological research, advanced diagnostics and technologies applied to medicine. From this perspective, Technoscience is working to build an ecosystem capable of supporting projects with high scientific and industrial value, facilitating the transfer of knowledge into concrete solutions.
Tags
Technoscience across Applied Research, Technology Transfer and Biotech
This trajectory includes dialogue with figures such as Andrea Frustaci, a reference figure in cellular and molecular cardiology; Federico Cozzolino, a leading contributor to the development of biotech platforms based on neurotrophin-mimetic molecules; Federica Limana, engaged in translational research on cellular mechanisms involved in cardiac repair; Marco Tafani, active in experimental medicine and in the study of molecular disease mechanisms; and Angelo Vescovi, a leading figure in the fields of cell biology, regenerative medicine and bioethics.
The continuation of the dialogue with Gregg L. Semenza therefore confirms Technoscience's intention to position itself as a connecting node between frontier research and practical applications. In this vision, biotech is understood not only as a scientific sector, but as development infrastructure: a field in which knowledge, business, intellectual property and technological innovation can converge to generate new opportunities for the local area and the research system.
Biotech as a Strategic Area for Technoscience's Future
"The continuity of the scientific dialogue with the Nobel Laureate Gregg L. Semenza represents an element of great value for our innovation ecosystem," says Technoscience Director General, Eng. Stefano Di Rosa.
"The biotech will be one of the main areas of strategic development in the coming years. We are working to build an international network capable of connecting research, companies, universities and high-level scientific expertise, involving some of the most authoritative minds in Italy and internationally."
Technoscience thus reaffirms its commitment to building an innovation model based on strong scientific expertise, international relationships and the ability to turn research into development pathways. This direction sees biotech as one of the key drivers of the medicine of the future and as a strategic field for the growth of the Science Park.
How we turn ideas into biotech projects
Would you like to understand how we could work together on complex biotech projects, such as the one on glioblastoma? Below is a selection of in-depth pages on biopharmaceutical pipelines, biobanks, data management and AI, telemedicine, precision cardiology and TRL pathways. They are the starting point for turning a good idea into an operational pathway, from the initial concept through to clinical validation and market entry.
Careers & Skills
Industry & Technology Transfer
GREEN & AGRI-BIOTECH
Biopharmaceuticals & Therapies
Biotechnology for Health
Frequently Asked Questions
Choose Technoscience!
To rapidly assess a project in biotech and translational medicine - from oncology and neuroscience to precision cardiology and telemedicine - we ask for: a clear clinical or industrial question, the available evidence (including negative findings), access to data and samples where applicable, a draft protocol (including ethical aspects), and hypotheses on biomarkers and endpoints. In return, we offer technical and scientific due diligence, the design of a credible TRL pathway and, where appropriate, support with regulatory strategy, validation and scalability.
Biotech FAQ
The questions you ask us most often
It is an approach that defines the the actual biology of the disease (tissues, markers and omics profiles where indicated) and links it to diagnostic and therapeutic decisions diagnostic and therapeutic personalised. It does not stop at generic classifications or guidelines applied wholesale: it builds a individual pathway measurable through robust clinical endpoints.
An enabling role. The biobanks ensure traceable and comparable samples; the omics broaden the understanding of the underlying mechanisms (inflammatory, metabolic and genetic). When integrated with rigorous protocols and real-world data, make reproducible the evidence and accelerate translation towards clinical trials or clinical adoption.
